OliX (226950.KQ) has signed a new licensing agreement with its existing partner, China's Hansoh Pharmaceutical, covering two siRNA sequences targeting two different genes. The agreement is separate from the companies' earlier joint development deal and follows five years of collaboration. Hansoh receives worldwide exclusive development and commercialization rights to one OliX-discovered, designed and validated sequence for each gene. OliX will receive a non-refundable upfront payment, development, approval and commercialization milestones, and sales-linked running royalties, although the deal value and upfront amount were not disclosed. The agreement uses what OliX calls a "sequence-level selective exclusivity model," allowing the company to retain or separately license other sequences targeting the same genes. OliX CEO Lee Dong-ki said the deal demonstrates Hansoh's confidence in the competitiveness and development potential of sequences derived through OliX's siRNA platform and said the company would continue creating flexible development and commercialization opportunities.